Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N; Yin, Xiangfan; Kossenkov, Andrew V; Liu, Qin; Zhang, Gao; Krepler, Clemens; Cheng, Chaoran; Wei, Zhi; Somasundaram, Rajasekharan; Karakousis, Giorgos; Xu, Wei; Morrissette, Jennifer Jd; Lu, Yiling; Mills, Gordon B; Sullivan, Ryan J; Benchun, Miao; Frederick, Dennie T; Boland, Genevieve; Flaherty, Keith T; Weeraratna, Ashani T; Herlyn, Meenhard; Amaravadi, Ravi; Schuchter, Lynn M; Burd, Christin E; Aplin, Andrew E; Xu, Xiaowei; Villanueva, Jessie.
EMBO Mol Med; 10(5)2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29650805